New developments in the treatment of osteoarthritis – focus on biologic agents

Código QR

New developments in the treatment of osteoarthritis – focus on biologic agents

Jose Ignacio Torrero,1 Carlos Martínez2 1BioTrauma Centre, Escaldes, Principality of Andorra; 2University of Illinois Hospital and Health Sciences System, Chicago, IL, USA Abstract: Osteoarthritis (OA) is one of the most common diseases around the world. Medical, social, and financial co...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Torrero JI, Martínez C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/42d743533a7d4b669d716675b5143794
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

A measure of treatment response: patient and physician satisfaction with traditional NSAIDs for osteoarthritis control
por: Taylor SD, et al.
Publicado: (2013)

The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents
por: Reimold AM
Publicado: (2012)

Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis &ndash; a systematic evaluation of the literature
por: Tran TN, et al.
Publicado: (2013)

The pain-relieving qualities of exercise in knee osteoarthritis
por: Susko AM, et al.
Publicado: (2013)

Serum anticyclic citrullinated protein antibody titers are correlated with the response to biological agents in patients with rheumatoid arthritis
por: Takahashi R, et al.
Publicado: (2014)

Unique aspects of pain reduction in osteoarthritis of the knee with LMWF-5A
por: McGrath B
Publicado: (2015)

Comparison of long-term efficacy between biological agents following tumor necrosis factor inhibitor failure in patients with rheumatoid arthritis: a prospective cohort study
por: Patricia Bogas, et al.
Publicado: (2021)

Obesity paradox in sarcopenia and knee osteoarthritis: comment on the article by Andrews et al
por: Kamal Mezian, et al.
Publicado: (2021)

New and emerging therapies for the treatment of rheumatoid arthritis
por: Michael G Feely
Publicado: (2010)

The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life
por: Roy Fleischmann
Publicado: (2009)

Association of Low Physical Activity Levels With Gait Patterns Considered at Risk for Clinical Knee Osteoarthritis Progression
por: Kerry E. Costello, et al.
Publicado: (2021)

Intra-articular Hyaluronic Acid for Osteoarthritis of the Knee in the United States: A Systematic Review of Economic Evaluations
por: Margaret Mordin, et al.
Publicado: (2021)

Clinical efficacy of intra-articular injections in knee osteoarthritis: a prospective randomized study comparing hyaluronic acid and betamethasone
por: Trueba Davalillo CA, et al.
Publicado: (2015)

Efficacy of a natural mineral complex in North American adults with osteoarthritis of the knee: a randomized double-blind placebo-controlled study
por: Evans M, et al.
Publicado: (2014)

Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
por: Fabrizio Cantini, et al.
Publicado: (2009)

Update on the therapy of adult-onset Still’s disease with a focus on IL-1-inhibition: a systematic review
por: Claudia Kedor, et al.
Publicado: (2021)

Different T cells' distribution and activation degree of Th17 CD4+ cells in peripheral blood in patients with osteoarthritis, rheumatoid arthritis, and healthy donors: preliminary results of the MAGENTA CLICAO study
por: Lurati A, et al.
Publicado: (2015)

The epidemiology and treatment of gout
por: McGill NW
Publicado: (2011)

Combination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations
por: Scolnik M, et al.
Publicado: (2011)

Cocaine-induced vasculitis: is this a new trend?
por: Garc&iacute;a P&eacute;rez MR, et al.
Publicado: (2013)

Treatment of systemic-onset juvenile arthritis with canakinumab
por: Peitz J, et al.
Publicado: (2015)

Certolizumab in the long-term treatment of rheumatoid arthritis
por: Scott DL, et al.
Publicado: (2011)

Optimal dose of etanercept in the treatment of rheumatoid arthritis
por: Curtis EM, et al.
Publicado: (2014)

Tocilizumab in the treatment of systemic juvenile idiopathic arthritis
por: Murakami M, et al.
Publicado: (2012)

Long-term treatment of rheumatoid arthritis with adalimumab
por: Murdaca G, et al.
Publicado: (2013)

Advances in diagnostic and treatment options in patients with fibromyalgia syndrome
por: Jill M Recla
Publicado: (2010)

Advances in diagnostic and treatment options in patients with fibromyalgia syndrome
por: Ali Gur, et al.
Publicado: (2009)

Calcium pyrophosphate crystal deposition disease: diagnosis and treatment
por: Rosales-Alexander JL, et al.
Publicado: (2014)

Retrospective analysis of treatment modalities in diabetic muscle infarction
por: Onyenemezu I, et al.
Publicado: (2014)

Long-term use of adalimumab in the treatment of rheumatic diseases
por: Charalampos Papagoras, et al.
Publicado: (2009)

Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis
por: Montepaone M, et al.
Publicado: (2014)

Current options for the treatment of Paget&rsquo;s disease of the bone
por: Daniela Merlotti, et al.
Publicado: (2009)

Applications of transcriptomics in support of drug development for osteoarthritis
por: Hélène Kaplon, et al.
Publicado: (2021)

Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis
por: Augustine JM, et al.
Publicado: (2012)

Anakinra and related drugs targeting interleukin-1 in the treatment of cryopyrin- associated periodic syndromes
por: Bachove I, et al.
Publicado: (2014)

Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome
por: Pierre Quartier
Publicado: (2011)

Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis
por: Masahiko Mihara, et al.
Publicado: (2011)

Childhood risk factors for developing fibromyalgia
por: Olivieri P, et al.
Publicado: (2012)

Efficacy and Safety of Etanercept Biosimilars Compared With the Originator for Treatment of Juvenile Arthritis: A Prospective Observational Study
por: Franz Thiele, et al.
Publicado: (2021)

Novel treatments for osteoarthritis: a recent update
por: Wu Y, et al.
Publicado: (2018)